Iscar for Supplemental Care in Stage IV Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-09-30

Study Completion Date

2004-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00283478

Non-Small Cell Lung Cancer

COMPLETED NA

Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)

NCT01448668

Pancreas Cancer

UNKNOWN

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

NCT01448655

Colorectal Cancer

UNKNOWN

A Prospective Dose Finding Study of Iscador Infusion

NCT04376931

Advanced Cancer

UNKNOWN PHASE1/PHASE2

Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer

NCT02948309

Pancreatic Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

See Brief Summary

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Iscar

Intervention Type DRUG

mistletoe

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage IV NSCLC patients who receive standard chemotherapy

Exclusion Criteria

* Known allergy to Viscum Album L.
* Concomitant use of other mistletoe products
* Concomitant use of mushroom glucan and proteoglycan extracts
* Concomitant use of thymus extract products
* Inability to self-report quality of life utilizing assessment tools
* Ongoing steroid or ACTH therapy
* Co-morbid immunocompromised state
* Pregnancy
* Participation in other clinical trials

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No